Replies to post #29131 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

Michele B. Kaufman, PharmD seemingly came to same conclusions by omitting Pfizer and Purdue from her prestigious list for Sept 2012.


Of noted interest is that ELI-216 is the only agonist/anatagonist listed by Drug Watch's advisory board member Michele B. Kaufman, PharmD.

http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/382012/789672/article.pdf

"ELI-216/oxycodone/naltrexone

Elite Pharmaceuticals

an oral, long-acting opioid receptor antagonist (abuse resistant
opioid combination)/for the treatment of pain
phase 3"

One has to wonder why Drug Watch's Dr. Kaufman, did not include any of the Pfizer and Purdue ongoing clinical studies in her listed "heads-up on pharmaceuticals in late-stage development"

Dr. Kaufman has highly acclaimed credentials with extensive experience in Pharmaceuticals and would know of all the ongoing phase 3 trials from which she compiled her Sept 2012 list.

http://primeinc.org/faculty/biography/362/Michele_B_Kaufman,_PharmD,_B_Pharm,_RPh